<DOC>
	<DOCNO>NCT00227370</DOCNO>
	<brief_summary>The study evaluate efficacy safety prolong , continuous course Valganciclovir ( Valgan ) prevention CMV compare 3 month Vaglanciclovir , standard care upon initiation study , 12 month Valganciclovir .</brief_summary>
	<brief_title>Comparison Oral Valganciclovir Placebo Prevention Cytomegalovirus ( CMV ) After Lung Transplantation</brief_title>
	<detailed_description>A multi-center two phase , double-blind , placebo control , randomize prospective study 130 lung transplant recipient . Patients screen consented prior transplant . All consent patient receive IV ganciclovir within 24 hour transplant 14 day . Patients enroll Phase I study open label safety efficacy analysis three month oral valganciclovir adult transplant recipient risk CMV . After completion 3 month open label therapy , patient meet criterion Phase II study randomize 9 month blind therapy ( Placebo/Valgan ) . Phase II study design assess efficacy short course sequential IV ganciclovir follow oral valganciclovir compare extended period oral valganciclovir prophylaxis prevention CMV disease risk lung transplant recipient</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Inclusion Criteria Phase I : Adult lung transplant recipient age 18 old At risk CMV ( donor recipient serology must positive CMV ) Adequate hematological renal function , On intravenous ( IV ) ganciclovir within 24 hour surgery Agreement use effective method contraception Negative pregnancy Tolerate oral medication within 2 week transplant Negative baseline CMV PCR Able understand sign inform consent Exclusion Criteria Phase 1 : Repeat transplantation Mechanical ventilation study entry Oral intravenous ganciclovir treatment outside study protocol Invasive fungal infection Participation another investigational study Acute CMV infection disease AntiCMV therapy within 30 day enrollment Uncontrolled diarrhea malabsorption Allergic reaction study drug Required use prohibit medication Lactating woman Pregnancy Renal failure Inclusion Criteria Phase II : Negative serial post transplant PCRs day 75 Negative bronchial culture CMV Adequate hematological renal function day 75 IV ganciclovir 2 week post operation open label day 90 Effective contraceptive Negative pregnancy Exclusion Criteria Phase II : Renal failure Serious adverse event ( SAE ) relate study drug CMV disease ( study endpoint ) Withdraw consent Phase II</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Acute rejection</keyword>
	<keyword>Non-CMV infection</keyword>
	<keyword>Resistance</keyword>
</DOC>